TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.

Autor:	Johnson WT; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Ganesan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Epstein-Peterson ZD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Moskowitz AJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Stuver RN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Maccaro CR; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Galasso N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chang T; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Khan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Aypar U; Department of Pathology, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY., Lewis NE; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Zelenetz AD; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Palomba ML; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Matasar MJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Noy A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Hamilton AM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Hamlin P; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Caron PC; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Straus DJ; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Intlekofer AM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Lee Batlevi C; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Kumar A; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Owens CN; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Sauter CS; Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH., Falchi L; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Lue JK; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Vardhana SA; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY., Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY., Dogan A; Department of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY., Schultz ND; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Arcila ME; Department of Pathology, Molecular Diagnostic Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY., Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2023 Sep 12; Vol. 7 (17), pp. 5172-5186.
DOI:	10.1182/bloodadvances.2023009953
Abstrakt:	Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival. We identified 132 patients who met these criteria. Clinical factors correlating with an increased risk of progression (by multivariate analysis) included advanced-stage disease and bone marrow involvement. The only somatic genetic aberrancies correlating with inferior progression-free survival (PFS) were TP53 mutations and TP53/17p deletions. PFS remained inferior when stratifying by TP53 mutation status, with a median PFS of 4.5 months for PTCL with a TP53 mutation (n = 21) vs 10.5 months for PTCL without a TP53 mutation (n = 111). No TP53 aberrancy correlated with inferior overall survival (OS). Although rare (n = 9), CDKN2A-deleted PTCL correlated with inferior OS, with a median of 17.6 months vs 56.7 months for patients without CDKN2A deletions. This retrospective study suggests that patients with PTCL with TP53 mutations experience inferior PFS when treated with curative-intent chemotherapy, warranting prospective confirmation. (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu